Brought to you by 
Satsuma Pharmaceuticals spins out of SNBL, raises $12.3mm Series A round
12 Jan 2017
Executive Summary
New San Francisco-based company Satsuma Pharmaceuticals Inc. (focused on migraine therapeutics) was recently spun out of Japanese CRO Shin Nippon Biomedical Laboratories Ltd. (SNBL) and concurrently brought in $12.3mm through a Series A round co-led by RA Capital Management and TPG Biotech, which both added members to the new company's board. One other investor joined the round, according to the Form D.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Nasal
-
Drug Delivery
Deal Status
- Final
Deal Type
-
Financing
- Spin-Off
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Satsuma Pharmaceuticals spins out of SNBL, raises $12.3mm Series A round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice